{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:10:10Z","timestamp":1793398210073,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01222-y","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T08:27:57Z","timestamp":1741076877000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed\/refractory multiple myeloma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-1652","authenticated-orcid":false,"given":"James A.","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4273-5780","authenticated-orcid":false,"given":"Mikhaila","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald C.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Cahoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2111-2461","authenticated-orcid":false,"given":"Kelley","family":"Julian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0568-0781","authenticated-orcid":false,"given":"Charlotte B.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelynn","family":"Granger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly M.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4547-7534","authenticated-orcid":false,"given":"Shebli","family":"Atrash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailey","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"McElwee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Elsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2473-6528","authenticated-orcid":false,"given":"Jack","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joslyn","family":"Rudoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3168-2521","authenticated-orcid":false,"given":"Zahra","family":"Mahmoudjafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria R.","family":"Nachar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"1222_CR1","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41591-018-0068-9","volume":"24","author":"C Rooney","year":"2018","unstructured":"Rooney C, Sauer T. Modeling cytokine release syndrome. Nat Med. 2018;24:705\u20136.","journal-title":"Nat Med"},{"key":"1222_CR2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1222_CR3","doi-asserted-by":"crossref","unstructured":"Mahmoudjafari Z, Ali A, Davis J, Sandahl T, Nachar V, Mancini R. Seamless navigation of bispecific therapies: optimizing management and outpatient access with a focus on coordination. J Adv Pract Oncol. 2024;15:1-16.","DOI":"10.6004\/jadpro.2024.15.8.15"},{"key":"1222_CR4","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1182\/blood.2023022432","volume":"143","author":"JL Crombie","year":"2024","unstructured":"Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil L, et al. Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapy. Blood. 2024;143:1565\u201375.","journal-title":"Blood"},{"key":"1222_CR5","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","volume":"25","author":"P Rodriguez-Otero","year":"2024","unstructured":"Rodriguez-Otero P, Usmani S, Cohen AD, van de Donk N, Leleu X, Gallego Perez-Larraya J, et al. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024;25:e205\u2013e16.","journal-title":"Lancet Oncol"},{"key":"1222_CR6","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/cncr.34756","volume":"129","author":"TG Martin","year":"2023","unstructured":"Martin TG, Mateos MV, Nooka A, Banerjee A, Kobos R, Pei L, et al. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed\/refractory multiple myeloma. Cancer. 2023;129:2035\u201346.","journal-title":"Cancer"},{"key":"1222_CR7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495\u2013505.","journal-title":"N Engl J Med"},{"key":"1222_CR8","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e46.","journal-title":"Lancet Oncol"},{"key":"1222_CR9","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","volume":"38","author":"C Riedhammer","year":"2024","unstructured":"Riedhammer C, Bassermann F, Besemer B, Bewarder M, Brunner F, Carpinteiro A, et al. Real-world analysis of teclistamab in 123 RRMM patients from Germany. Leukemia. 2024;38:365\u201371.","journal-title":"Leukemia"},{"key":"1222_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01003-z","volume":"14","author":"M Mohan","year":"2024","unstructured":"Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V, et al. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J. 2024;14:35.","journal-title":"Blood Cancer J"},{"key":"1222_CR11","doi-asserted-by":"publisher","first-page":"308 e1","DOI":"10.1016\/j.jtct.2023.12.016","volume":"30","author":"D Dima","year":"2024","unstructured":"Dima D, Davis JA, Ahmed N, Jia X, Sannareddy A, Shaikh H, et al. Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience. Transplant Cell Ther. 2024;30:308 e1\u2013e13.","journal-title":"Transplant Cell Ther"},{"key":"1222_CR12","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1182\/blood-2023-180458","volume":"142","author":"D Dima","year":"2023","unstructured":"Dima D, Sannareddy A, Ahmed N, Davis JA, Shaikh H, Mahmoudjafari Z, et al. Toxicity and efficacy outcomes of teclistamab in patients with relapsed-refractory multiple myeloma (RRMM) above the age of 70 years: a multicenter study. Blood. 2023;142:3330.","journal-title":"Blood"},{"key":"1222_CR13","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1016\/S2152-2650(24)01974-8","volume":"24","author":"B Razzo","year":"2024","unstructured":"Razzo B, Grajales-Cruz A, Atrash S, Ferreri C, Goyal A, Pasvolsky O, et al. P-071 real-world experience with teclistamab for relapsed\/ refractory multiple myeloma from the U.S. Myeloma Immunotherapy Consortium. Clin Lymphoma Myeloma Leuk. 2024;24:S82\u2013S3.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1222_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00963-y","volume":"13","author":"SA Scott","year":"2023","unstructured":"Scott SA, Marin EM, Maples KT, Joseph NS, Hofmeister CC, Gupta VA, et al. Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience. Blood Cancer J. 2023;13:191.","journal-title":"Blood Cancer J"},{"key":"1222_CR15","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.1182\/blood-2023-187086","volume":"142","author":"A Kowalski","year":"2023","unstructured":"Kowalski A, Lykon JL, Diamond B, Coffey D, Kaddoura M, Maura F, et al. Tocilizumab prophylaxis for patients treated with teclistamab: a single-center experience. Blood. 2023;142:4709.","journal-title":"Blood"},{"key":"1222_CR16","unstructured":"Tocilizumab. In: Lexi-drugs online [database on the internet]. Hudson (OH): Lexicomp, Inc. 2024 [updated 20 Nov 2024; cited 22 Nov 2024] [Available from: Available from: http:\/\/online.lexi.com."},{"key":"1222_CR17","unstructured":"Dexamethasone. In: Lexi-drugs online [database on the internet]. Hudson (OH): Lexicomp, Inc. 2024 [updated 21 Nov 2024; cited 22 Nov 2024] [Available from: Available from: http:\/\/online.lexi.com."},{"key":"1222_CR18","doi-asserted-by":"crossref","unstructured":"Kauer J, Horner S, Osburg L, Muller S, Marklin M, Heitmann JS, et al. Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies. J Immunother Cancer. 2020;8:e000621.","DOI":"10.1136\/jitc-2020-000621"},{"key":"1222_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01048-0","volume":"14","author":"BA Costa","year":"2024","unstructured":"Costa BA, Flynn J, Nishimura N, Devlin SM, Farzana T, Rajeeve S, et al. Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma. Blood Cancer J. 2024;14:84.","journal-title":"Blood Cancer J"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01222-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01222-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01222-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T08:28:00Z","timestamp":1741076880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01222-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1222"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01222-y","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JAD: consultancy: Janssen. MR: consultancy: Janssen. ZM: consultancy: Janssen, Pfizer, Sanofi. SA: Research Funding: GSK, AMGEN, Karyopharm; Honoraria: Janssen. KJ: consultancy: Pfizer, Janssen (J&J), and BioLineRx. CBW: consultancy: Pfizer. JK: honoraria GPCR Therapeutics, Legend Biotech; Consultancy: Janssen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"All centers obtained institutional review board approval, which granted a waiver of patient consent, and the study was conducted in accordance with the Declaration of Helsinki. All centers obtained institutional review board approval, reference # Pro00122996.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"32"}}